Author

NaMi Lee

Observed name: Nami Lee

Institution: Yuhan (South Korea)

Observed institutions: Yuhan (South Korea), Hanmi Pharmaceutical (South Korea)

ORCID: 0009-0007-8213-7666

Observed ORCID: 0009-0007-8213-7666

OpenAlex ID: A5101705726

A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors

2021 · Byoung Chul Cho, Ji-Youn Han, et al. · Journal of Thoracic Oncology · 99

A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer

2019 · Tae-Yong Kim, Hye Sook Han, et al. · Gastric Cancer · 37

Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201

2024 · Byoung Chul Cho, Ji-Youn Han, et al. · Lung Cancer · 12

Effects of Acid-Reducing Agents on the Pharmacokinetics of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

2022 · Bomin Kim, Jungwook Lee, et al. · Advances in Therapy · 3

Abstract CT068: A phase 1/2, open-label, multicenter, first-in-human study to evaluate the safety, pharmacokinetics, and anti-tumor activity of YH32367 in patients (pts) with HER2+ locally advanced/metastatic (a/m) solid tumors

2025 · Do-Youn Oh, SunYoung Rha, et al. · Cancer Research · 2

Works count: 5

Citation count: 153

H-index: 3

I10-index: 3